Aurotech Launches Drug Lifecycle Tracking Solution
The solution, DLTA, is built on a project-management platform overlaid with knowledge of drug development and FDA requirements.
Aurotech, Inc., an established management and IT consulting firm is entering the pharmaceutical market with the launch of its Drug Lifecycle Tracking Application (DLTA). DLTA is built on a project-management platform overlaid with knowledge of drug development and FDA requirements. The result is custom-mapped workflow management for the entire drug development lifecycle. Users have the ability to track, manage and monitor projects from centralized dashboards and in-system collaboration for hand-offs between teams.
For CROs, DLTA can be implemented to improve clinical trial workflows across large teams or projects. For a pharmaceutical organization, the solution can function as an end-to-end work management platform, to replace disparate systems.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
